24570 Federal Register / Vol. 87, No. 80 / Tuesday, April 26, 2022 / Notices 

for Public Comments’’ or by using the 

search function. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ website address at 

website address at: https://

www.cms.gov/Regulations-andGuidance/Legislation/ 

PaperworkReductionActof1995/PRAListing.html. 

FOR FURTHER INFORMATION CONTACT: 

William Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: LTCH CARE 

Data Set for the Collection of Data 

Pertaining to the Long-Term Care 

Hospital Quality Reporting Program; 

Use: We are requesting an extension to 

the Long-Term Care Hospital Continuity 

Assessment Record and Evaluation Data 

Set (LTCH CARE Data Set or LCDS) 

Version 5.0 that will be effective on 

October 1, 2022. 

On November 2, 2021 the Centers for 

Medicare & Medicaid Services (CMS) 

issued a final rule (86 FR 62240) which 

finalized proposed modifications to the 

effective date for the reporting of 

measures and certain standardized 

patient assessment data in the Longterm Care Hospital Quality Reporting 

Program (LTCH QRP). Per the final rule 

CMS will require LTCHs to start 

collecting assessment data using LCDS 

Version 5.0 beginning October 1, 2022. 

The information collection request for 

LCDS Version 5.0 was re-approved on 

December 7, 2021 with an October 1, 

2022 implementation date. CMS is 

asking for an extension of the approved 

LCDS Version 5.0, which currently 

expires on December 31, 2022. 

The LTCH CARE Data Set is used to 

collect, submit, and report quality data 

to CMS for compliance with the LongTerm Care Hospital Quality Reporting 

Program (LTCH QRP). Form Number: 

CMS–10409 (OMB control number: 

0938–1163); Frequency: Occasionally; 

Affected Public: Private Sector: Business 

or other for-profit and not-for-profit 

institutions; Number of Respondents: 

415; Total Annual Responses: 204,936; 

Total Annual Hours: 145,831. (For 

policy questions regarding this 

collection contact Christy Hughes at 

410–786–5662.) 

Dated: April 20, 2022. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2022–08823 Filed 4–25–22; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Neurological Sciences 

Training Initial Review Group NST–1 Study 

Section (NST–1 Clinician K Application 

Review). 

Date: May 23–24, 2022. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: William C. Benzing, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS, NIH, NSC, 6001 Executive 

Boulevard, Suite 3204, MSC 9529, Bethesda, 

MD 20892–9529, 301–496–0660, benzingw@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: April 20, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08833 Filed 4–25–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Engineered Tumor 

Infiltrating Lymphocytes for Cancer 

Therapy 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this Notice to Iovance 

Biotherapeutics, Inc. (‘‘Iovance’’), 

headquartered in San Carlos, CA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before May 11, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Andrew Burke, Ph.D., 

Senior Technology Transfer Manager, 

NCI Technology Transfer Center, 

Telephone: (240)-276–5484; Email: 

andy.burke@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

E–170–2009: Inducible Interleukin-12 

1. US Provisional Patent Application 

61/174,046, filed April 30, 2009 (E–170– 

2009–0–US–01); 

2. International Patent Application 

PCT/US2010/031988, filed April 22, 

2010 (E–170–2009–0–PCT–02); 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 80 / Tuesday, April 26, 2022 / Notices 24571 

3. Australian Patent 2010241864, 

issued June 5, 2014 (E–170–2009–0– 

AU–03); 

4. Canadian Patent 2,760,446, issued 

January 2, 2018 (E–170–2009–0–CA– 

04). 

5. European Patent 2424887, issued 

September 30, 2015 (E–170–2009–0– 

EP–05); and a. Validated in DE, FR and 

GB 

6. United States Patent 8,556,882, 

issued October 15, 2013 (E–170–2009– 

0–US–06). 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the 

following: 

‘‘The use of the Licensed Patent 

Rights to develop, manufacture, 

distribute, sell, and use autologous 

tumor infiltrating lymphocyte (TIL) 

adoptive cell therapy products for the 

treatment of cancer. Specifically 

excluded from this Licensed Field of 

Use are adoptive cell therapy products 

genetically engineered to express a 

chimeric antigen receptor and/or T cell 

receptor.’’ 

E–170–2009 is primarily directed to 

recombinant constructs for the 

inducible expression of Interleukin-12 

(IL–12). IL–12 has been reported to be 

an important immunostimulatory 

cytokine; however, its clinical utility 

has been constrained, in part, by doselimiting toxicity following systemic 

administration. The subject invention 

potentially addresses this limitation by 

operatively associating a nuclear factor 

of activated T cells (NFAT) promoter 

with the coding sequence for IL–12. TIL 

engineered to express these constructs 

produce and secrete IL–12 at the site of 

antigen binding (exempli gratia, in the 

tumor microenvironment). 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument establishing that 

the grant of the license would not be 

consistent with the requirements of 35 

U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: April 20, 2022. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2022–08795 Filed 4–25–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Immigration and Customs 

Enforcement 

[OMB Control Number 1653–0026] 

Agency Information Collection 

Activities; Extension of a Currently 

Approved Collection: Information 

Relating to Beneficiary of Private Bill 

AGENCY: U.S. Immigration and Customs 

Enforcement, Department of Homeland 

Security. 

ACTION: 60-Day notice. 

SUMMARY: In accordance with the 

Paperwork Reduction Act (PRA) of 

1995, the Department of Homeland 

Security (DHS), U.S. Immigration and 

Customs Enforcement (ICE) will submit 

the following Information Collection 

Request (ICR) to the Office of 

Management and Budget (OMB) for 

review and clearance. 

DATES: Comments are encouraged and 

will be accepted until June 27, 2022. 

ADDRESSES: All submissions received 

must include the OMB Control Number 

1653–0026 in the body of the 

correspondence, the agency name and 

Docket ID ICEB–2006–0015. All 

comments received will be posted 

without change to http://

www.regulations.gov, including any 

personal information provided. Submit 

comments via the Federal eRulemaking 

Portal website at http://

www.regulations.gov under e-Docket ID 

number ICEB–2006–0015. 

FOR FURTHER INFORMATION CONTACT: If 

you have questions related to this 

revision, please contact: Ina Farka, ERO 

Policy Unit, (202) 732–3270, eropolicy@

ice.dhs.gov. (This is not a toll-free 

number. Comments are not accepted via 

telephone message). 

SUPPLEMENTARY INFORMATION: 

Comment 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information should address one or more 

of the following four points: 

(1) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(2) Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

(1) Type of Information Collection: 

Extension of a Currently Approved 

Collection. 

(2) Title of the Form/Collection: 

Information Relating to Beneficiary of 

Private Bill. 

(3) Agency form number, if any, and 

the applicable component of the 

Department of Homeland Security 

sponsoring the collection: G–79A; U.S. 

Immigration and Customs Enforcement. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Primary: State, Local, or Tribal 

Government. This form is used by ICE 

to obtain information from beneficiaries 

and/or interested parties in Private Bill 

cases when requested to report by the 

Committee on the Judiciary. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond: 100 responses at 60 minutes (1 

hour) per response. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: The total estimated annual 

hour burden is 100 hours. 

Dated: April 21, 2022. 

Scott Elmore, 

PRA Clearance Officer, U.S. Immigrations 

and Customs Enforcement, Department of 

Homeland Security. 

[FR Doc. 2022–08856 Filed 4–25–22; 8:45 am] 

BILLING CODE 9111–28–P 


jspears on DSK121TN23PROD with NOTICES1